AGY vs. AMYT, APH, BXP, ANCR, STX, VLG, EAH, DNL, PXS, and MXC
Should you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Shield Therapeutics (STX), Venture Life Group (VLG), ECO Animal Health Group (EAH), Diurnal Group (DNL), Provexis (PXS), and Argent BioPharma (MXC). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Allergy Therapeutics vs. Its Competitors
Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.
Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.
5.9% of Allergy Therapeutics shares are owned by institutional investors. 4.7% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -72.86%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.
In the previous week, Allergy Therapeutics had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Amryt Pharma. Allergy Therapeutics' average media sentiment score of 0.59 beat Amryt Pharma's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the news media.
Summary
Amryt Pharma and Allergy Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.
Get Allergy Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AGY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allergy Therapeutics Competitors List
Related Companies and Tools
This page (LON:AGY) was last updated on 10/9/2025 by MarketBeat.com Staff
